SCHEMBL22323913

SCHEMBL22323913

COc1cc2c(=O)n(C)cnc2cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.48
KDM4E B2RXH2 1/20 0.46
TNF P01375 3/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
ACVR1 Q04771 2/20 0.42
IP6K1 Q92551 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29377697 1.00 HDAC6 (0.48) HDAC6KDM4ETNFTSHRMAPK1
SCHEMBL28689988 0.94 HDAC6 (0.48) HDAC6KDM4ETNFTSHRMAPK1
SCHEMBL28703844 0.92 HDAC6 (0.45) HDAC6KDM4ETNFTSHRMAPK1
SCHEMBL4728366 0.87 HDAC6 (0.59) HDAC6KDM4ETNFTSHRMAPK1
SCHEMBL22323965 0.86 KDM4E (0.42) HDAC6KDM4ETNFTSHRMAPK1
SCHEMBL29447051 0.86 KDM4E (0.42) HDAC6KDM4ETNFTSHRMAPK1
SCHEMBL24165356 0.83 HDAC6 (0.49) HDAC6KDM4ETNFTSHRMAPK1
SCHEMBL19645655 0.82 HDAC6 (0.51) HDAC6KDM4ETNFTSHRMAPK1
SCHEMBL24166144 0.79 HDAC6 (0.49) HDAC6KDM4ETNFTSHRMAPK1
SCHEMBL4782862 0.79 HDAC6 (0.51) HDAC6KDM4ETNFTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4192454-B1 AZABICYCLO-AMINO-TRIAZINE COMPOUNDS FOR MODULATING SPLICING FOR THE TREATMENT OF NEUROLOGICAL DISEASES SKYHAWK THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
WO-2025109474-A1 SUBSTITUTED IMIDAZOARENES AND METHODS OF THEIR USE NOVARTIS AG (CH) 2025-05-30 WO disclosed
US-20240002375-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE REMIX THERAPEUTICS INC. 2024-01-04 US disclosed
CN-117015536-A 2- (indazol-5-yl) -6- (piperidin-4-yl) -1, 7-naphthyridine derivatives and related compounds as modulators of nucleic acid splicing and treatment of proliferative diseases 雷密克斯医疗公司 2023-11-07 CN disclosed
US-20230331718-A1 COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-10-19 US disclosed
US-20230331718-A1 COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-10-19 US disclosed
EP-4192454-A1 COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2023-06-14 EP disclosed
CN-116171153-A Compositions for modulating splicing 斯基霍克疗法公司 2023-05-26 CN disclosed
EP-4175956-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES Remix Therapeutics Inc. (US) 2023-05-10 EP disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
CN-114126613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-03-01 CN disclosed
WO-2022031838-A1 COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed
WO-2022006550-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES REMIX THERAPEUTICS INC. (US) 2022-01-06 WO disclosed
WO-2022006550-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES REMIX THERAPEUTICS INC. (US) 2022-01-06 WO disclosed
EP-3920926-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 EP disclosed
WO-2020163541-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331718-A1 COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPE HDAC6 1597/4885KDM4E 2388/4885TNF 4695/4885
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 HDAC6 1838/4885KDM4E 2530/4885TNF 4612/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 HDAC6 1714/4885KDM4E 2036/4885TNF 4873/4885
US-20240002375-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE POLRMT, HNRNPA1, SNRPA HDAC6 1007/4885KDM4E 3380/4885TNF 3112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.